Skip to content

Non-invasive Intervention for Apnea of Prematurity

Neuromodulation of Limb Proprioceptive Afferents Using a Vibratory Device to Decrease Apnea, Intermittent Hypoxia and Bradycardia of Prematurity.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02641249
Enrollment
19
Registered
2015-12-29
Start date
2014-10-31
Completion date
2016-02-29
Last updated
2017-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Apnea of Prematurity, Bradycardia, Hypoxia

Brief summary

Purpose of Study: Apnea of Prematurity (AOP) is common, affecting the majority of infants born \<34 weeks gestational age (GA). Apnea is accompanied by intermittent hypoxia (IH), which contributes to multiple pathologies, including retinopathy of prematurity (ROP), sympathetic ganglia injury, impaired pancreatic islet cell and bone development, and neurodevelopmental disabilities. Standard of care for AOP/IH includes prone positioning, positive pressure ventilation, and caffeine therapy, none of which is optimal. The objective is to support breathing in premature infants by using a simple, non-invasive vibratory device placed over limb proprioceptor fibers, an intervention using the principle that limb movements facilitate breathing. Methods Used: Premature infants (23-34 wks GA) with clinical evidence of AOP/IH were enrolled 1 week after birth. Caffeine therapy was not a reason for exclusion. Small vibration devices were placed on one hand and one foot and activated in a 6 hour ON/OFF sequence for a total of 24 hours. Heart rate, respiratory rate, oxygen saturation (SpO2), and breathing pauses were continuously collected.

Detailed description

Aim: To study the effect of limb proprioceptive stimulation using a vibratory device on apneic events, intermittent hypoxic episodes and bradycardias in a premature infant with apnea of prematurity. The objective is to provide support and to assist impaired ventilation and oxygenation in apnea of prematurity (AOP). Recurrent apnea and accompanying resultant intermittent hypoxic (IH) episodes are significant concerns commonly encountered in premature infants, and optimal management is a challenge to neonatologists. AOP is defined as a pause of breathing for more than 15-20 seconds or accompanied by oxygen desaturation (SpO2\<80% for\>4s) and bradycardia (heart rate\<2/3 of baseline for\>4s), in infants born less than 37 weeks of gestation \[Moriette G et al., 2010\]. When these pauses are longer (\> 15s), they are frequently prolonged by obstructed inspiratory efforts, most likely secondary to loss of upper airway tonic activity \[Martin RJ et al., 2012\]. In extremely low birth weight (ELBW) infants, the incidence of IH progressively increases over the first 4 weeks of postnatal life, followed by a plateau and subsequent decline between 6-8 weeks. The incidence of AOP correlates inversely with gestational age and birth weight. Nearly all infants born \<29 weeks gestation or \<1,000 g \[Robertson CM et al., 2009\], 54% at 30 to 31 weeks, 15% at 32 to 33 weeks, and 7% at 34 to 35 weeks gestation exhibit AOP \[Martin RJ et al\]. Both animal and human evidence show that immature or impaired respiratory control and the resultant IH exposure contribute to a variety of pathophysiologic issues via pro-inflammatory and/or pro-oxidant cascade as well as cellular mechanisms, e.g., apoptosis, leading to acute and chronic morbidities (e.g. retinopathy of prematurity, altered growth and cardiovascular regulation, disrupting zinc homeostasis which hampers insulin production and there by predisposing to diabetes in later life, cerebellar injuries and neurodevelopmental disabilities) \[Martin RJ et al., 2004, Pae EK et al., 2011, 2014, \]. Current standard of care for AOP includes prone positioning, continuous positive airway pressure (CPAP) or nasal intermittent positive pressure ventilation (NIPPV) to prevent pharyngeal collapse and alveolar atelectasis, and methylxanthine therapy (caffeine, theophylline), which is the mainstay of treatment of central apnea \[Reher et al., 2008; Pantalitschka T et al., 2009; Moretti C et al., 2012; Henderson-Smart DJ et al., 2010\]. Apart from prone positioning, none of these interventions are optimal for early development. CPAP masks will distort the bony facial structure in early development, and methylxanthine interventions pose serious questions of neural development interactions. Hypothesis: Applying slight vibration to the limbs will reduce the number of breathing pauses, intermittent hypoxic episodes and bradycardias in apnea of prematurity.

Interventions

DEVICEVibration

A device providing vibrations is placed on the subject and vibration is turned on and off in a 6 hour on/off sequence. Heart rate, respiratory pauses and oxygen saturation are compared during vibration (intervention) and without vibration (no intervention) in the same subject.

Sponsors

University of California, Los Angeles
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE

Masking description

Open Label

Intervention model description

In the same subject there were 2 periods: Arm 1. 'No intervention' period (no vibrations) - two 6 hour epochs - total of 12 hours of 'No intervention' Arm 2. Experimental period (with vibrations) - two 6 hour epochs - total of 12 hours of 'vibration intervention' In the same subjects cardiorespiratory parameters - heart rate, respiratory rate and oxygen saturation were compared during the experimental period (vibration) and druing the no intervention period (no vibration).

Eligibility

Sex/Gender
ALL
Age
1 Weeks to No maximum
Healthy volunteers
No

Inclusion criteria

1. Gestational age \> 23 weeks, \< 34 weeks 2. At least 1 week old at recruitment 3. Diagnosis of apnea of prematurity (AOP) 4. Caffeine treatment will not be an exclusion

Exclusion criteria

1. Infants with major congenital anomalies/malformations which will influence central nervous system and long-term outcomes in these infants, such as cardiac anomalies (except for Patent Ductus Arteriosus or Ventricular Septal Defect) or major neurological malformations, like meningoencephalocele, holoprosencephaly etc. 2. Neonates who have apnea from airway issues like laryngomalacia or tracheomalacia 3. Neonates with history of hypoxic ischemic encephalopathy or Grade IV intraventricular hemorrhage

Design outcomes

Primary

MeasureTime frameDescription
Change in Total Number of Episodes of Apnea/Breathing Pauses During Intervention and Without Intervention12 hours of intervention/12 hours of no interventionThe total number of apneas/breathing pauses will be compared during periods of vibration (intervention) to periods of no vibrations (no intervention).

Secondary

MeasureTime frameDescription
Change in the Total Number of Intermittent Hypoxic Episodes to <90% Lasting >5 Seconds/Episode During the Intervention and Without Intervention12 hours of intervention/12 hours of no interventionThe total number of intermittent hypoxic episodes to \<90% (pulse oximetry) lasting \>5 seconds/episode will be compared during periods of vibration (intervention) to periods of no vibrations (no intervention).
Change in the Total Number of Bradycardia Episodes (<100 Beats Per Minute (Bpm), at Least 5 Seconds Long) During Intervention and Without the Intervention12 hours of intervention/12 hours of no interventionThe total number of bradycardia episodes to \<100 bpm lasting \>5 seconds/episode will be compared during periods of vibration (intervention) to periods of no vibrations (no intervention).

Countries

United States

Participant flow

Recruitment details

Dates of Recruitment: 10/2014-2/2016 Location: Hospital

Participants by arm

ArmCount
All Subjects
In the same subject cardiorespiratory parameters - heart rate, respiratory rate and oxygen saturation were compared during the procedure (vibration) and without procedure (no vibration). The same subject had both control and treatment periods. Vibration: A device providing vibrations is placed on the subject and vibration is turned on and off in a 6 hour on/off sequence. Heart rate, respiratory pauses and oxygen saturation are compared during vibration (intervention) and without vibration (no intervention) in the same subject.
19
Total19

Baseline characteristics

CharacteristicAll Subjects
Age, Categorical
<=18 years
19 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
Age, Continuous28.9 weeks
STANDARD_DEVIATION 2.1
Birth Weight1213 grams
STANDARD_DEVIATION 510
Caffeine use16 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
4 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
15 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Oxygen use15 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
1 Participants
Race (NIH/OMB)
Black or African American
5 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
13 Participants
Region of Enrollment
United States
15 participants
Sex: Female, Male
Female
8 Participants
Sex: Female, Male
Male
11 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 19
serious
Total, serious adverse events
0 / 19

Outcome results

Primary

Change in Total Number of Episodes of Apnea/Breathing Pauses During Intervention and Without Intervention

The total number of apneas/breathing pauses will be compared during periods of vibration (intervention) to periods of no vibrations (no intervention).

Time frame: 12 hours of intervention/12 hours of no intervention

Population: Premature neonates (29 +/- 2.5 weeks gestational age at birth), with a diagnosis of apnea of prematurity

ArmMeasureValue (MEAN)Dispersion
No VibrationChange in Total Number of Episodes of Apnea/Breathing Pauses During Intervention and Without Intervention284.13 breathing pausesStandard Error 41.175
VibrationChange in Total Number of Episodes of Apnea/Breathing Pauses During Intervention and Without Intervention174.27 breathing pausesStandard Error 22.985
Secondary

Change in the Total Number of Bradycardia Episodes (<100 Beats Per Minute (Bpm), at Least 5 Seconds Long) During Intervention and Without the Intervention

The total number of bradycardia episodes to \<100 bpm lasting \>5 seconds/episode will be compared during periods of vibration (intervention) to periods of no vibrations (no intervention).

Time frame: 12 hours of intervention/12 hours of no intervention

Population: Premature neonates (29 +/- 2.5 weeks gestational age at birth), with a diagnosis of apnea of prematurity

ArmMeasureValue (MEAN)Dispersion
No VibrationChange in the Total Number of Bradycardia Episodes (<100 Beats Per Minute (Bpm), at Least 5 Seconds Long) During Intervention and Without the Intervention50.53 bradycardiasStandard Error 23.2
VibrationChange in the Total Number of Bradycardia Episodes (<100 Beats Per Minute (Bpm), at Least 5 Seconds Long) During Intervention and Without the Intervention14.93 bradycardiasStandard Error 5.674
Secondary

Change in the Total Number of Intermittent Hypoxic Episodes to <90% Lasting >5 Seconds/Episode During the Intervention and Without Intervention

The total number of intermittent hypoxic episodes to \<90% (pulse oximetry) lasting \>5 seconds/episode will be compared during periods of vibration (intervention) to periods of no vibrations (no intervention).

Time frame: 12 hours of intervention/12 hours of no intervention

Population: Premature neonates (29 +/- 2.5 weeks gestational age at birth), with a diagnosis of apnea of prematurity

ArmMeasureValue (MEAN)Dispersion
No VibrationChange in the Total Number of Intermittent Hypoxic Episodes to <90% Lasting >5 Seconds/Episode During the Intervention and Without Intervention151.67 IH eventsStandard Error 24.286
VibrationChange in the Total Number of Intermittent Hypoxic Episodes to <90% Lasting >5 Seconds/Episode During the Intervention and Without Intervention109.67 IH eventsStandard Error 22.661

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026